« Return to News | CROs/Service Providers

Premier Research Group Acquires Two More CROs

Friday, July 13, 2007 09:32 AM

London-based contract research organization (CRO) Premier Research Group continued its acquisition spree by purchasing two more CROs. Premier Research bought ARS Inc., based in Boston, and D-TARGET SA, located in Switzerland. Premier has acquired six CROs since 2004 when it went public.

Premier expects ARS will strengthen its presence in the New England biotech market while D-Target's medical device focus will bring expanded expertise in that area to customers in both the United States and Europe. ARS also has expertise in Oracle Clinical.

The acquisition of the two companies continues the Premier’s strategy of building an international business both organically and through strategic acquisitions.

Dr. Simon Yaxley, chief executive officer of Premier Research, said, "Both firms clearly represent a further important step in our strategy of building a leading international contract research organization."

Yaxley added that both companies have strong order books. "Both also offer a number of complementary synergies to the enlarged Group and further strengthen Premier Research's position in the international CRO market," he said.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.